Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial of MB-103 to the brains of patients with HER2-positive breast cancer with brain metastases

Trial Profile

A phase I trial of MB-103 to the brains of patients with HER2-positive breast cancer with brain metastases

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2018

At a glance

  • Drugs MB-103 (Primary)
  • Indications Brain metastases; Glioblastoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 30 Oct 2018 According to a Mustang Bio media release, this trial is being conducted by City of Hope, a world-renowned independent cancer research and treatment centre.
    • 30 Oct 2018 Status changed from planning to recruiting, according to a Mustang Bio media release.
    • 02 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top